Singapore's Healthcare AI Framework Gets Major Upgrade: HSA Achieves World-First WHO Recognition

Date: March 10, 2026

Singapore has taken a decisive leap forward in healthcare AI governance, announcing a revised regulatory framework that addresses the rapidly evolving landscape of artificial intelligence in medicine. On March 10, 2026, Minister for Health Ong Ye Kung revealed that the Health Sciences Authority (HSA) has become the first national regulatory authority in the world to attain the World Health Organization's highest Maturity Level 4 rating for medical device regulation.

A New Global Benchmark

The achievement positions Singapore as a global reference point for medical device and healthcare AI regulation. In his speech at the International Medical Device Regulators Forum at NTUC Centre, Mr. Ong emphasized that this recognition affirms Singapore's commitment to balancing innovation with patient safety.

"Ultimately, health regulation comprises a network of international cooperation, in which Singapore will be one of the key nodes," Mr. Ong stated. The HSA's new status means that other countries—including Australia, Hong Kong, Malaysia, the Philippines, South Africa, Switzerland, Thailand, and the United Kingdom—can reference HSA approvals to expedite their own regulatory processes.

Revising the Healthcare AI Framework

The revised healthcare AI framework, co-developed by MOH and HSA, specifically addresses recent developments in artificial intelligence, including generative AI. Key features include:

The framework aims to enable more innovations that augment the healthcare workforce while ensuring safety and efficacy. HSA has also announced it welcomes registration applications for AI-developed drugs—a significant policy shift that could accelerate the arrival of computationally discovered pharmaceuticals in Singapore.

Singapore's Biomedical Hub Ambitions

Adjunct Professor Raymond Chua, HSA's chief executive, highlighted the economic dimension of this achievement: "The future of healthcare will not be shaped by innovation alone, but by the wisdom with which we govern it."

HSA will now work alongside universities, academic medical centres, hospitals, and A*STAR to strengthen the biomedical innovation pipeline. The regulatory body will also partner with other public sector agencies to enhance clinical trial capabilities and grow the number of trials in Singapore.

Looking ahead, Singapore will consolidate various agency functions—including HSA's—to better support the growth of the biomedical industry. The country will explore opportunities to align companies' product offerings with priority disease areas such as cardiovascular diseases, diabetes, and metabolic disorders.

A Gateway to Global Markets

Singapore's small market size is no longer a limitation. As Mr. Ong pointed out: "When a product succeeds in Singapore, it sends a strong positive signal to global markets." With this WHO recognition, Singapore is poised to become not just a market of six million people, but a gateway for market access to hundreds of millions across Asia and beyond.

The city-state's evolution from a trading post to a financial centre, and now to a biomedical hub, reflects its strategic approach to remaining relevant in an AI-driven world. By establishing trust, integrity, and credibility in healthcare regulation, Singapore is carving out a unique position in the global health technology landscape.

Related Resources

For more insights on Singapore's technology ecosystem and innovation landscape, visit sup.sg, your source for startup news and digital transformation coverage in Singapore. Also explore dominance.sg for comprehensive analysis of Singapore's tech initiatives and AI developments.

Source: The Straits Times